Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

DHEA access threatened?

John S James

    AIDS Treatment News
    |May 24, 2005
    PubMed
    Summary
    This summary is machine-generated.

    Dehydroepiandrosterone (DHEA) was nearly banned in the U.S. in 2005 due to anti-steroid legislation, which would have hindered medical research and treatment options.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Activism and online fundraising: overview.

    AIDS treatment news·2007
    Same author

    "Fundathon": toward massively multiplayer online fundraising games.

    AIDS treatment news·2007
    Same authorSame journal

    Selling digital art in bulk through prepaid URLs.

    AIDS treatment news·2007
    Same authorSame journal

    Financial accounts that can reproduce, inherit, and evolve.

    AIDS treatment news·2007
    Same authorSame journal

    AIDS search engine wanted: what to do now?

    AIDS treatment news·2007
    Same author

    Prisoner death rate very high immediately after release.

    AIDS treatment news·2007
    Same journal

    New kind of antiretroviral, KP-1461; clinical trial recruiting. Interview with Stephen Becker, M.D.

    AIDS treatment news·2008
    Same journal

    Flu shot reminder.

    AIDS treatment news·2008
    Same journal

    Is cure possible for HIV?

    AIDS treatment news·2007
    See all related articles

    Area of Science:

    • Endocrinology
    • Pharmacology
    • Public Health Policy

    Background:

    • Dehydroepiandrosterone (DHEA) faced a potential ban in the U.S. in January 2005.
    • Legislation targeting steroids in sports threatened to restrict DHEA's availability and research.
    • Physicians could have been prohibited from prescribing DHEA, impacting patient care.

    Discussion:

    • The proposed ban on DHEA highlighted the challenges in regulating substances with both performance-enhancing and therapeutic potential.
    • Restrictions could have significantly impeded ongoing and future medical research into DHEA's diverse applications.
    • The incident underscored the delicate balance between sports integrity and legitimate medical use of certain compounds.

    Key Insights:

    • A near-total ban on DHEA in 2005 could have severely limited its medical applications and research.

    Related Experiment Videos

  • The legislation's broad scope risked impacting treatments beyond athletic performance enhancement.
  • Vigilance is crucial to prevent the loss of potentially valuable therapeutic agents due to regulatory overreach.

    • Outlook:

    • Continued monitoring of regulatory landscapes concerning DHEA and similar compounds is essential.
    • Further research is needed to fully elucidate DHEA's therapeutic benefits and risks.
    • Public awareness and advocacy may be necessary to ensure continued access to DHEA for medical purposes.